Thoughts on signal detection in pharmacovigilance

Drug Safety

Volumn 30, Issue 7, 2007, Pages 603-606

  Shakir, Saad A W ^a  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE OUTCOME; AUTOMATION; CAUSAL ATTRIBUTION; CAUSE OF DEATH; CONFERENCE PAPER; DATA BASE; DOSE RESPONSE; DRUG INFORMATION; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOLLOW UP; GENERAL PRACTICE; HUMAN; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; SIGNAL DETECTION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CAUSALITY; GREAT BRITAIN; HUMANS; PHARMACEUTICAL PREPARATIONS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 34447127555     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200730070-00005     Document Type: Conference Paper

References (4)

1. McBride WG. Thalidomide and congenital abnormalities. Lancet 1961; 278 (7216): 1358
2. Shakir SAW. Prescription-event monitoring. In: Strom BL, editor. Pharmacoepidemiology. 4th ed. Chichester: John Wiley & Sons Ltd; 2005. 203-16
3. Jick H. The discovery of drug-induced illness. N Engl J Med 1977; 296 (9): 481-5
4. Clarke A, Deeks JJ, Shakir SAW. An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets. Drug Saf 2006; 29 (2): 175-81